TG Therapeutics (TGTX) Tops Q3 EPS by 6c

TG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of ($0.28), $0.06 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $38.1 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• SanDisk stock target lifted at Bernstein to $3000 on new memory LTAs
• Phinia to acquire stoba Group in deal expected to close in Q4 2026
• Merck (MRK) PT Raised to $155 at Scotiabank